March 24, 2015—Members of a House health subcommittee expressed strong support for the 340B program during a hearing today, with some stating more should be done to clarify program requirements and enhance program transparency. … [Read more...]
House 340B Hearing Rescheduled for March 24
HRSA, GAO, and OIG are slated to testifyMarch 17, 2015—The House Energy & Commerce Health Subcommittee has rescheduled a hearing on the 340B program for March 24, according to a notation on the subcommittee's home page. The session was originally slated for March 5 but postponed due to a snowstorm. … [Read more...]
HRSA’s Wakefield Elevated to Number Two Post at HHS
Jim Macrae, who has run FQHC's parent bureau, will run HRSA on acting basisMarch 12, 2015—Mary Wakefield, who has led the Heath Resources and Services Administration since 2009, was today named Acting Deputy Secretary of Health and Human Services. … [Read more...]
Prescription Drug Spending Jumped 13.1% Last Year, Study Finds
Hepatitis C drugs helped fuel the biggest year-to-year increase since 2003March 11, 2015—Prescription drug spending skyrocketed in 2014, rising 13.1 percent over 2013 for all drugs – the highest rate in a decade – and a record-setting 30.9 percent for specialty drugs, according to a new report by pharmacy benefit management company Express Scripts. … [Read more...]
Hospital Survey: Genentech’s Cancer Drug Distribution Change Raises Costs, Disrupts Care
Move to specialty channel also raises risk of 340B noncompliance, hospitals warnMarch 6, 2015—Genentech's decision last fall to move its top-selling cancer drugs Avastin, Herceptin, and Rituxan into the specialty distribution channel has cost hospitals more than $300 million and disrupted patient care, a survey of more than 200 hospitals has found. Nearly two out of five hospitals (39 percent) surveyed said the change affects their risk of 340B program … [Read more...]
MedPAC: No 340B Recommendations to Congress This Year
June report will include a chapter about 340B, but it won't suggest any changesMarch 6, 2015—The Medicare Payment Advisory Commission will include a chapter about the 340B program in its June report to Congress, Chairman Glenn Hackbarth said during yesterday's commission meeting. But it will make no recommendations about 340B at this time, he added, and it remains up in the air whether the commission will make such recommendations at all. … [Read more...]
HRSA Has Sharpened 340B Oversight, Agencies Tell House Panel
Written testimony posted in advance of hearing, which has been postponedMarch 4, 2015—The Health Resources and Services Administration has significantly strengthened its oversight of the 340B program in recent years, government witnesses say in written testimony submitted in advance of a congressional hearing on the drug discount program. … [Read more...]